Featured Stock: Geron Corporation (NASDAQ:GERN)

Geron Corporation (NASDAQ:GERN) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.

Geron Corporation (NASDAQ:GERN) lost -3.1 Percent and closed its previous trading session at $3.75. The stock traded with the average Volume of 4.55 Million at the end of last session.

Geron Corporation (NASDAQ:GERN) has the Market Capitalization of 647.14 Million. The Stock has its 52-week High of $6.68 and 52-Week Low of $1.74 and it touched its 52-week high on 03/22/18 and 52-Week Low on 11/14/17


The company reported its last earnings Actual EPS of $-0.04/share. While, the analyst predicted that the company could provide an EPS of $-0.04/share.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 6.2% where SMA50 and SMA200 are 2.22% and 25.03% respectively.

The company shows its Return on Assets (ROA) value of -22.2%. The Return on Equity (ROE) value stands at -23.1%. While it’s Return on Investment (ROI) value is -28.2%.

Geron Corporation (NASDAQ:GERN) currently has a Weekly Volatility of 6.46% percent while its Monthly Volatility is at 6.83% percent. While talking about Performance of the Stock, Geron Corporation currently has a Weekly performance of 5.34%, monthly performance percentage is 4.46 percent, Quarterly performance is 3.31 percent, 6 months performance shows a percent value of 56.25% and Yearly Performance is 74.42 percent.

Company Profile:

Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking pluripotent stem cells as a potential source for the manufacturing of replacement cells and tissues. Lastly, the company is researching nuclear transfer as a potential mechanism for generating genetically matched cells and tissues.